Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This approval, based on the positive results from the SURMOUNT-CN clinical trial, makes tirzepatide the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for obesity treatment in China, which is expected to enhance its market positioning in the country, says GlobalData
So, theres going to be a wide spectrum of winners and losers in the food industry from the growth of GLP-1 drugs: some companies will be very negatively impacted, others might see little impact, while others could even benefit
Clinical trials show GLP-1 agonists reduce appetite signaling through the hypothalamus and increase satiety hormones, creating meaningful metabolic changes
It may provide anti-inflammatory support
US$ 25.42
US$ 28.15
US$ 28.14
US$ 28.63
US$ 25.06
US$ 24.61
US$ 22.18
US$ 28.38
US$ 25.43
US$ 21.27
US$ 23.69
US$ 21.82
US$ 20.25
